BTSG vs CGON: fair value comparison
BrightSpring Health Services, Inc. and CG Oncology, Inc. · Updated 2026-10-19
CGON has no fair-value estimate yet: no usable analyst consensus or too few reported quarters. Within Healthcare, BTSG currently ranks higher by quality score.
| BTSG | CGON | |
|---|---|---|
| Verdict | Undervalued | No estimate yet |
| Last price | $60.87 | $59.85 |
| 12-month range | $31.36–$72.91 | $37.37–$80.68 |
| Rank by discount to fair value | #35 of 108 Healthcare | — |
| Rank by quality score | #153 of 301 Healthcare | #154 of 301 Healthcare |
| Quality grade | D | D |
| Leverage | Moderate | Low |
| Margin trend | Stable | Expanding |
| Revenue growth | Strong | — |
| RSI zone | Neutral | Oversold |
| 50/200-day trend | Uptrend | Mixed |
| 52-week position | The upper-middle quarter | The upper-middle quarter |
Full single-stock breakdowns: BTSG fair value analysis · CGON fair value analysis